153 related articles for article (PubMed ID: 28650468)
1. MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance.
Wang J; Kho DH; Zhou JY; Davis RJ; Wu GS
Oncogene; 2017 Oct; 36(43):5939-5947. PubMed ID: 28650468
[TBL] [Abstract][Full Text] [Related]
2. Regulation of MKP-1 expression and MAPK activation by PARP-1 in oxidative stress: a new mechanism for the cytoplasmic effect of PARP-1 activation.
Racz B; Hanto K; Tapodi A; Solti I; Kalman N; Jakus P; Kovacs K; Debreceni B; Gallyas F; Sumegi B
Free Radic Biol Med; 2010 Dec; 49(12):1978-88. PubMed ID: 20920579
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibition protects mitochondria and reduces ROS production via PARP-1-ATF4-MKP-1-MAPK retrograde pathway.
Hocsak E; Szabo V; Kalman N; Antus C; Cseh A; Sumegi K; Eros K; Hegedus Z; Gallyas F; Sumegi B; Racz B
Free Radic Biol Med; 2017 Jul; 108():770-784. PubMed ID: 28457938
[TBL] [Abstract][Full Text] [Related]
4. ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells.
Wang J; Zhou JY; Wu GS
Cancer Res; 2007 Dec; 67(24):11933-41. PubMed ID: 18089824
[TBL] [Abstract][Full Text] [Related]
5. Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance.
Wang Z; Xu J; Zhou JY; Liu Y; Wu GS
Cancer Res; 2006 Sep; 66(17):8870-7. PubMed ID: 16951204
[TBL] [Abstract][Full Text] [Related]
6. High level of mitogen-activated protein kinase phosphatase-1 expression is associated with cisplatin resistance in osteosarcoma.
Wang Z; Zhou JY; Kanakapalli D; Buck S; Wu GS; Ravindranath Y
Pediatr Blood Cancer; 2008 Dec; 51(6):754-9. PubMed ID: 18726921
[TBL] [Abstract][Full Text] [Related]
7. MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1.
Liu Y; Niu Z; Lin X; Tian Y
Cancer Gene Ther; 2017 May; 24(5):208-214. PubMed ID: 28281524
[TBL] [Abstract][Full Text] [Related]
8. Effects of poly (ADP-ribosyl) polymerase (PARP) inhibitor on cisplatin resistance & proliferation of the ovarian cancer C13* cells.
Zhang J; Kan Y; Tian Y; Wang Z; Zhang J
Indian J Med Res; 2013 Mar; 137(3):527-32. PubMed ID: 23640560
[TBL] [Abstract][Full Text] [Related]
9. Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin.
Rojo F; González-Navarrete I; Bragado R; Dalmases A; Menéndez S; Cortes-Sempere M; Suárez C; Oliva C; Servitja S; Rodriguez-Fanjul V; Sánchez-Pérez I; Campas C; Corominas JM; Tusquets I; Bellosillo B; Serrano S; Perona R; Rovira A; Albanell J
Clin Cancer Res; 2009 May; 15(10):3530-9. PubMed ID: 19417026
[TBL] [Abstract][Full Text] [Related]
10. c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer.
Rincón R; Zazo S; Chamizo C; Manso R; González-Alonso P; Martín-Aparicio E; Cristóbal I; Cañadas C; Perona R; Lluch A; Eroles P; García-Foncillas J; Albanell J; Rovira A; Madoz-Gúrpide J; Rojo F
Mol Cancer Ther; 2016 Nov; 15(11):2780-2790. PubMed ID: 27599524
[TBL] [Abstract][Full Text] [Related]
11. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
12. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.
Washington MN; Suh G; Orozco AF; Sutton MN; Yang H; Wang Y; Mao W; Millward S; Ornelas A; Atkinson N; Liao W; Bast RC; Lu Z
Cell Death Dis; 2015 Aug; 6(8):e1836. PubMed ID: 26247722
[TBL] [Abstract][Full Text] [Related]
13. Docosahexaenoic acid induces apoptosis in lung cancer cells by increasing MKP-1 and down-regulating p-ERK1/2 and p-p38 expression.
Serini S; Trombino S; Oliva F; Piccioni E; Monego G; Resci F; Boninsegna A; Picci N; Ranelletti FO; Calviello G
Apoptosis; 2008 Sep; 13(9):1172-83. PubMed ID: 18679798
[TBL] [Abstract][Full Text] [Related]
14. STAMBPL1 promotes breast cancer cell resistance to cisplatin partially by stabilizing MKP-1 expression.
Liu R; Yang G; Bao M; Zhou Z; Mao X; Liu W; Jiang X; Zhu D; Ren X; Huang J; Chen C
Oncogene; 2022 Apr; 41(16):2265-2274. PubMed ID: 35236965
[TBL] [Abstract][Full Text] [Related]
15. DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling.
Li J; Pan C; Boese AC; Kang J; Umano AD; Magliocca KR; Yang W; Zhang Y; Lonial S; Jin L; Kang S
Clin Cancer Res; 2020 Jul; 26(14):3843-3855. PubMed ID: 32341033
[TBL] [Abstract][Full Text] [Related]
16. Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells.
Wang J; Zhou JY; Zhang L; Wu GS
Cell Cycle; 2009 Oct; 8(19):3191-8. PubMed ID: 19755862
[TBL] [Abstract][Full Text] [Related]
17. New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors.
Folk WP; Kumari A; Iwasaki T; Cassimere EK; Pyndiah S; Martin E; Homlar K; Sakamuro D
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948122
[TBL] [Abstract][Full Text] [Related]
18. JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells.
Zhao Z; Wang J; Tang J; Liu X; Zhong Q; Wang F; Hu W; Yuan Z; Nie C; Wei Y
Biochem J; 2012 Jun; 444(2):291-301. PubMed ID: 22394200
[TBL] [Abstract][Full Text] [Related]
19. Interplay of MKP-1 and Nrf2 drives tumor growth and drug resistance in non-small cell lung cancer.
Wang H; Liu K; Chi Z; Zhou X; Ren G; Zhou R; Li Y; Tang X; Wang XJ
Aging (Albany NY); 2019 Dec; 11(23):11329-11346. PubMed ID: 31811110
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin.
Persons DL; Yazlovitskaya EM; Cui W; Pelling JC
Clin Cancer Res; 1999 May; 5(5):1007-14. PubMed ID: 10353733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
